secwatch.observer — SEC 8-K summary
======================================

Issuer:     DMK PHARMACEUTICALS Corp (—)
CIK:        0000887247
Form:       8-K
Filed at:   2023-09-08T23:59:59+00:00
Accession:  0001387131-23-010995
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adamis Pharma changes name to DMK Pharmaceuticals, ticker to DMK, pivots to substance use disorders
--------------------------------------------------------------------------------

- Adamis Pharmaceuticals renamed DMK Pharmaceuticals effective September 6, 2023; new Nasdaq ticker 'DMK' begins September 8, 2023.
- Strategic focus shifts to small-molecule therapies for substance use disorders, including opioid overdose treatment ZIMHI® and clinical compound DPI-125.
- DPI-125 targets opioid use disorder and moderate-to-severe pain; company expects milestones by end 2024 including transdermal delivery, safety study, and abuse liability study.
- No stockholder vote required; CUSIP unchanged; no impact on existing shareholder rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887247/000138713123010995/0001387131-23-010995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887247/000138713123010995/dmk-8k_090623.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-010995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer